Welcome to the March 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we explore the expanded approval for a JAK2 peripheral blood assay, the safety and efficacy of low-dose hypomethylators in low-risk myelodysplastic syndrome and MPNs, and the use of idasanutlin in refractory polycythemia vera (PV). We also highlight recently published treatment strategies for essential thrombocythemia and PV, research focused on how the presence of specific genetic mutations in patients with post-MPN acute myeloid leukemia may play a role in response to therapy, and the role of the IL28B genotype in MPNs.
I’m also excited to share that we’ve been hard at work on a special case-based video roundtable discussion during which three experts in the field and I will highlight the current state of MPN treatment and management. Stay tuned for this valuable resource in an upcoming newsletter.
If you haven’t done so yet, check out last year’s video roundtable panel discussion, “Perspectives on the Collaborative Management of Myeloproliferative Neoplasms” as a refresher.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
I hope you find this to be a useful and enduring resource in your practice!
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus